Effets secondaires de l’ivermectine utilisée dans le traitement de la gale

Sparsa, A.; Bonnetblanc, J.‐M.; Peyrot, I.; Loustaud‐Ratti, Véronique; Vidal, É.; Bédane, C.

doi:10.1016/s0151-9638(06)71044-4

Cited by 17 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scabies is a common parasitic infestation that is difficult to eradicate [29]. Drugs that are presently used for scabies have several limitations, including resistance development [7], toxicity, long-term damage [8], and practical difficulties in management.…”

Section: Discussionmentioning

confidence: 99%

“…Ivermectin is used extensively for scabies. Since the introduction of ivermectin for the treatment of scabies, reports of adverse events have been rare although this drug can cause cardiac dysfunction and hepatitis [29]. Propolis is a nontoxic natural product; however, some cases of allergy and contact dermatitis to this compound have been described, mainly among beekeepers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers as predictive tools to test the in vivo anti-sarcoptic mange activity of propolis in naturally infested rabbits

et al. 2018

View full text Add to dashboard Cite

The present study was designed to investigate the use of specific biomarkers, such as albumin, serum total protein, aspartate amino transferase (AST), globulin, alanine amino transferase (ALT), serum cortisol and alkaline phosphatase (ALP), as predictive tools for sarcoptic mange in rabbits. A total of 40 naturally infested rabbits were equally divided into four groups.Thirty infested rabbits were administered with three different treatments (propolis,ivermectin, and propolis with ivermectin) and were compared to10 infested un-treated rabbits. The impact of treatment was assessed via microscopic examination of skin scrapings, clinical signs, and blood measurements relating to the liver. The present study demonstrated that topical application of 10% propolis ointment resulted in complete recovery from clinical signs and complete absence of mites based on microscopic examination after 10–15 days of treatment. Moreover, AST, ALP, ALT, and cortisol were determined to be acceptable biomarkers to track the response of diseased rabbits to the therapeutic use of propolis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Biomarkers as predictive tools to test the in vivo anti-sarcoptic mange activity of propolis in naturally infested rabbits

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Our systematic search of the literature for non-neurological adverse events found 10 cases where ivermectin was associated with cutaneous reactions [11][12][13][14][15], nephropathy [16], psychiatric disorders [17,18], hepatic disorders [19,20] and multiorgan dysfunction syndrome [21]. Clinical trials and observational studies have reported common adverse events such as headache, pruritus, muscle pain, cough, dyspnea, nausea, vomiting, diarrhea, blurred vision, postural hypotension and confusion and more anecdotal effects such as serious skin reactions and edematous swelling [22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World

et al. 2021

View full text Add to dashboard Cite

Background Ivermectin is known to cause severe encephalopathies in subjects infected with loiasis, an endemic parasite in Sub-Saharan Africa (SSA). In addition, case reports have described ivermectin-related serious adverse drug reactions (sADRs) such as toxidermias, hepatic and renal disorders. The aim of this study was to identify suspected sADRs reported after ivermectin administration in VigiBase, the World Health Organization’s global individual case safety reports database and analyze their frequency relative to the frequency of these events after other antinematodal drugs reported in SSA and other areas of the world (ROW). Methods All antinematodal-related sADRs were extracted from VigiBase. Disproportionality analyses were conducted to investigate nervous, cutaneous, psychiatric, respiratory, renal, hepatic and cardiac suspected sADRs reported after ivermectin and benzimidazole drug administration across the world, in SSA and RoW. Principal findings 2041 post-ivermectin or post-benzimidazole suspected sADRs were identified including 667 after ivermectin exposure (208 in SSA and 459 in the RoW). We found an increased reporting for toxidermias, encephalopathies, confusional disorders after ivermectin compared to benzimidazole drug administration. Encephalopathies were not only reported from SSA but also from the RoW (adjusted reporting odds ratios [aROR] 6.30, 95% confidence interval: 2.68–14.8), highlighting the fact these types of sADR occur outside loiasis endemic regions. Conclusion We described for the first time suspected sADRs associated with ivermectin exposure according to geographical origin. While our results do not put in question ivermectin’s excellent safety profile, they show that as for all drugs, appropriate pharmacovigilance for adverse reactions is indicated.

show abstract

“…Although it has been demonstrated to block SARS-CoV-2 replication in-vitro, evidence in humans is lacking (Caly et al 2020). It has no significant impact on the cardiovascular system, except for cases of hypotension and tachycardia without hemodynamic instability (Sparsa et al 2006).…”

Section: Antiviral Agentsmentioning

confidence: 99%

The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review

et al. 2022

View full text Add to dashboard Cite

The coronavirus disease-2019 (COVID-19) pandemic has become a major global health problem. COVID-19 is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and exhibits pulmonary and extrapulmonary effects, including cardiovascular involvement. There are several attempts to identify drugs that could treat COVID-19. Moreover, many patients infected with COVID-19 have underlying diseases, particularly cardiovascular diseases. These patients are more likely to develop severe illnesses and would require optimized treatment strategies. The current study gathered information from various databases, including relevant studies, reviews, trials, or meta-analyses until April 2022 to identify the impact of SARS-CoV-2 treatment on the cardiovascular system. Studies have shown that the prognosis of patients with underlying cardiovascular disease is worsened by COVID-19, with some COVID-19 medications interfering with the cardiovascular system. The COVID-19 treatment strategy should consider many factors and parameters to avoid medication-induced cardiac injury, mainly in elderly patients. Therefore, this article provides a synthesis of evidence on the impact of different COVID-19 medications on the cardiovascular system and related disease conditions.

show abstract

Effets secondaires de l’ivermectine utilisée dans le traitement de la gale

Cited by 17 publications

References 20 publications

Biomarkers as predictive tools to test the in vivo anti-sarcoptic mange activity of propolis in naturally infested rabbits

Biomarkers as predictive tools to test the in vivo anti-sarcoptic mange activity of propolis in naturally infested rabbits

Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World

The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review

Contact Info

Product

Resources

About